Trevogrumab: The Myostatin-Blocking Antibody (Not a Peptide) for Muscle Loss

Trevogrumab is a fully human monoclonal antibody, made by Regeneron under the code REGN1033, that grabs and neutralizes myostatin (GDF-8), the body's main "stop growing" signal for muscle. It lands on this peptide-focused site for one reason: it is constantly mislabeled as a "myostatin peptide," when it is nothing of the sort. It is a large biologic drug, roughly fifty times the size of a typical research peptide, that has only ever been given inside human clinical trials.

If you have searched "trevogrumab" and found nothing but reagent spec sheets, a one-paragraph encyclopedia stub, and pharma press releases, this page is the plain-English map of the whole molecule. If you arrived here chasing size and are weighing the legitimate options, our best peptides for muscle growth guide covers the compounds people can actually use, which trevogrumab is not. We cover what it actually is, why "antibody" and "peptide" are not interchangeable, how myostatin blockade works, what its sarcopenia and obesity trials really showed, how it compares to follistatin-344 and the wider myostatin-inhibitor drug class, and its honest status as an investigational biologic you cannot buy. Each section is a clear overview; the adjacent deep-dives point to dedicated guides so this page stays a clean hub.

Key Takeaways

• Trevogrumab (development code REGN1033) is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals, designed as a selective inhibitor of myostatin (GDF-8) (Wikipedia, "Trevogrumab", retrieved 2026-06-16).
• It is an antibody, not a peptide. Its molar mass is about 144,000 g/mol (~144 kDa), versus a few thousand for a typical peptide, so it is a large biologic drug, not a research-chemical peptide (Wikipedia, "Trevogrumab", retrieved 2026-06-16).
• It works by trapping circulating myostatin so myostatin cannot reach the activin type 2 receptors (ActRIIA/B), which lifts the brake on muscle growth (Wikipedia, "Trevogrumab", retrieved 2026-06-16).
• It has been tested only in humans inside clinical trials. A 253-patient Phase 2 sarcopenia study completed in 2015, and a 1,005-patient Phase 2 obesity study (COURAGE) is ongoing (ClinicalTrials.gov NCT01963598; NCT06299098, retrieved 2026-06-16).
• Its current story is muscle preservation during GLP-1 weight loss. In COURAGE, adding trevogrumab to semaglutide cut how much of the lost weight came from lean mass roughly in half at 26 weeks (Regeneron, EASD 2025-09-17, retrieved 2026-06-16).
• It is not FDA-approved and is not for sale. Trevogrumab is investigational; unlike follistatin-344, it is not part of the research-peptide gray market and there is no route to obtain it outside a trial.

What is trevogrumab?

Trevogrumab is a fully human monoclonal antibody, developed by Regeneron under the code REGN1033, that binds and neutralizes myostatin (GDF-8) to release the brake on muscle growth. It is a large biologic drug given by injection in clinical studies, not a supplement, not a peptide, and not a product you can buy. Its whole existence is inside the regulated drug-development system.

In plain terms, an antibody is a Y-shaped protein the immune system normally uses to recognize and stick to a specific target. Trevogrumab is a lab-engineered version designed to stick to one thing: myostatin. Its chemical formula is C6374H9884N1696O2018S46 with a molar mass of about 144,037 g/mol, and it carries identifiers including CAS 1429201-24-0, UNII 87T4327873, KEGG D11242, and DrugBank DB15159 (Wikipedia, "Trevogrumab", retrieved 2026-06-16). It was developed by Regeneron Pharmaceuticals, with Sanofi as an early collaborator on the muscle-loss work, and it is also seen under the code SAR391786.

The single most important fact about trevogrumab is its status: it is investigational, not approved by any regulator for any use, and it has only ever been administered to people inside clinical trials. Everything else in this guide should be read through that lens. If injectable proteins are new to you, the foundations are in our how peptides work guide.

Citation capsule. Trevogrumab (development code REGN1033; also SAR391786) is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals that acts as a selective inhibitor of myostatin (GDF-8). It is a large biologic, molar mass ~144,037 g/mol (formula C6374H9884N1696O2018S46), not a peptide. Identifiers: CAS 1429201-24-0; UNII 87T4327873; KEGG D11242; DrugBank DB15159. It is investigational and not approved by any regulator. Source: Wikipedia, "Trevogrumab," 2026.

Why is an antibody not a peptide?

An antibody and a peptide are different classes of molecule: a peptide is a short chain of amino acids (a few thousand daltons), while a monoclonal antibody like trevogrumab is a large, folded protein around 144,000 daltons, built and dosed completely differently. Calling trevogrumab a "peptide" is the single most common error in how it is described online, and it changes almost everything about how the drug behaves.

The size gap is the headline. A research peptide like follistatin-344 or BPC-157 is a small molecule by protein standards; trevogrumab is roughly fifty times heavier and far more structurally complex. That size drives three practical differences. First, antibodies cannot be casually mixed from a powder at home the way peptides are; they are manufactured in living cells and handled as finished biologic drugs. Second, antibodies typically last weeks in the bloodstream rather than minutes to hours, so they are dosed infrequently. Third, antibodies are reviewed and sold (if ever) as prescription biologics, not as "research chemicals."

Here is the core contrast in one place:

• Peptide (e.g. follistatin-344): short amino-acid chain, a few thousand daltons; short half-life; sold on the unapproved research-peptide market as a lyophilized powder.
• Monoclonal antibody (trevogrumab): large folded protein, ~144 kDa; long half-life; a clinical-stage biologic only available inside trials.
• Shared target, different tool: both can act on the myostatin pathway, but one is a broad binding protein and the other is a precision-engineered antibody.

This distinction is not pedantic. It is why trevogrumab does not appear on peptide vendor sites, why its dosing looks nothing like a peptide protocol, and why it follows a slow, regulated drug-development path instead.

How does trevogrumab work?

Trevogrumab works by binding and neutralizing myostatin (GDF-8), the protein that normally tells muscle to stop growing, so myostatin can no longer reach its receptors and the brake on muscle is released. It does not directly stimulate muscle; it removes a built-in limiter. This is the same overall idea behind every myostatin inhibitor, but trevogrumab does it with antibody-level precision against one ligand.

Myostatin is a member of the TGF-β family of signaling proteins, and its job is to keep muscle from growing without limit. Normally it docks onto the activin type 2 receptors (ActRIIA and ActRIIB) on muscle cells and triggers internal Smad2/3 signaling that suppresses growth. Wikipedia summarizes trevogrumab's action directly: "By binding and neutralizing myostatin, Trevogrumab prevents its interaction with activin type 2 receptors (ActRIIA/B), thereby reducing myostatin-mediated signaling and allowing increased muscle growth" (Wikipedia, "Trevogrumab", retrieved 2026-06-16).

You can picture the antibody as a sponge floating in the bloodstream that soaks up free myostatin before it can land on muscle. With less myostatin available to signal "stop," the natural pro-growth machinery has more room to operate. The same logic explains why blocking myostatin is attractive in any condition where muscle is wasting or under threat, from age-related decline to the muscle loss that can accompany rapid weight loss.

There is a subtle but important detail in where trevogrumab acts. It is a ligand trap, meaning it intercepts myostatin in the bloodstream rather than sitting on the muscle cell and blocking the receptor. That matters because the activin type 2 receptors are not exclusive to myostatin; activin A and several other TGF-β-family signals use the same receptors. By neutralizing myostatin specifically, trevogrumab leaves that broader signaling traffic mostly untouched, which is the selectivity its developers were aiming for. It is also the reason Regeneron pairs it with garetosmab in obesity studies: if you want to silence both myostatin and activin A, you need two targeted antibodies rather than one broad net. This precision is the deliberate trade-off of the antibody approach versus a wide-spectrum binding protein like follistatin.

The receptor-and-Smad signaling deep dive is its own topic; we keep it at overview level here. The key takeaway is the direction of the effect: trevogrumab lifts a brake rather than pressing an accelerator.

What has trevogrumab been tested for?

Trevogrumab has been studied in humans for two main goals: first to slow age-related muscle loss (sarcopenia), and more recently to protect muscle during GLP-1 weight loss in obesity. Both were run as Phase 2 clinical trials by Regeneron, and neither has led to an approved use. None of these are FDA-approved indications; they are the directions the program has explored.

The first chapter was sarcopenia. A Phase 2 study, NCT01963598, titled a "study of the safety and efficacy of 3-month subcutaneous REGN1033 treatment in patients with sarcopenia," enrolled 253 patients with Sanofi as collaborator and completed in February 2015, with the primary outcome being the percent change in total lean body mass measured by DEXA at week 12 (ClinicalTrials.gov NCT01963598, retrieved 2026-06-16). The trial design is worth noting because it tells you what the researchers were really chasing: total lean body mass was the headline, but the secondary outcomes were the ones that mattered for daily life, things like leg and chest press strength, gait speed, the Short Physical Performance Battery, a six-minute walk, hand-grip strength, and stair-climb power. In other words, the study was built to test whether more muscle on a scan would translate into a person who could actually walk, lift, and climb stairs better.

The broad read of that era of myostatin antibodies is sobering: they could nudge lean mass upward, but turning that into clear, meaningful gains in strength and physical function proved difficult, and trevogrumab did not advance to approval for sarcopenia. That disconnect, more mass without proportional function, was not unique to trevogrumab; it dogged the whole first generation of myostatin blockers and is part of why several were eventually shelved (see the comparison below). The lesson the field took away is that muscle quality and the nervous system's ability to recruit muscle matter as much as raw size, which is the unglamorous reality behind the more exciting headlines.

The second, current chapter is obesity, and it is a smarter reframing of the same tool. Rapid weight loss on GLP-1 drugs like semaglutide strips away not just fat but a meaningful share of muscle, so a myostatin blocker is being tested as an add-on to keep the muscle while the fat goes. That is the COURAGE trial, covered in the next section.

Our take: The sarcopenia result is the quietly important part of trevogrumab's story. "Lean mass went up but function did not clearly follow" is a recurring pattern across myostatin antibodies, and it is the honest backdrop to the more exciting obesity headlines. More lean tissue on a scan is not automatically more useful strength.

What did the obesity (COURAGE) trial show?

In the ongoing Phase 2 COURAGE trial, adding trevogrumab to semaglutide roughly halved the share of weight loss that came from muscle, and a three-drug combination preserved the most muscle while increasing fat loss. These are interim 26-week results from an investigational trial, not an approval, and the study is still running. The signal is about the quality of weight loss, not a new standalone muscle drug.

COURAGE (NCT06299098) is a 1,005-patient Phase 2 study, sponsored by Regeneron, testing trevogrumab with or without garetosmab (an anti-activin-A antibody) on top of semaglutide in people with obesity; it began in March 2024, is currently active and not recruiting, with primary completion estimated for May 2026 (ClinicalTrials.gov NCT06299098, retrieved 2026-06-16). At the EASD meeting in September 2025, Regeneron reported that on semaglutide alone about 33% of the weight lost was lean mass, whereas adding trevogrumab cut lean-mass loss to roughly 17% of the weight lost, and the triplet (semaglutide plus trevogrumab plus garetosmab) brought it to about 7% while pushing fat loss higher (Regeneron, "Results from Phase 2 COURAGE Trial… Presented at EASD," 2025, retrieved 2026-06-16).

The underlying biology was backed by a 2025 preclinical paper showing that blocking GDF-8 and activin A together "protects against GLP-1–induced muscle loss while enhancing fat loss" in obese mice and non-human primates (Mastaitis et al., Nature Communications, 2025, retrieved 2026-06-16). The lead investigator framed the human results as a meaningful opportunity to preserve muscle mass while enhancing fat loss. The important caveats: this is one Phase 2 trial, the headline outcomes are body-composition measures rather than long-term health endpoints, and longer 52-week data are still pending.

How does trevogrumab compare to follistatin-344 and other myostatin inhibitors?

Trevogrumab is one of several drugs aimed at the myostatin pathway, but it is the precise, myostatin-specific antibody on a regulated drug-development path, whereas follistatin-344 is a broad binding protein sold on the research-peptide market. They share a goal (more muscle, less wasting) but differ sharply in modality, breadth, and legitimacy.

The cleanest way to hold them apart is breadth and origin. Follistatin-344 is a natural-type binding protein that traps myostatin and activin together, a broad, upstream net; it is detailed in our follistatin-344 guide and sold as an unapproved research peptide. Trevogrumab is a precision antibody that neutralizes free myostatin specifically, developed inside Regeneron's clinical pipeline. A third family member, garetosmab, is an antibody against activin A, and others target the pathway at different points; bimagrumab, for example, blocks the ActRII receptor itself rather than the myostatin ligand.

The takeaway from the table is that "myostatin inhibitor" is a family, not a single drug, and trevogrumab is the Regeneron antibody currently riding the GLP-1 muscle-preservation wave. The full drug-class breakdown and the follistatin comparison are their own topics; we keep them brief here to avoid overlapping those dedicated guides.

Our take: People shopping the research-peptide market sometimes ask for "trevogrumab" as if it sits next to follistatin-344 in a vendor catalog. It does not. They occupy opposite ends of the legitimacy spectrum: one is a precision biologic in registered Phase 2 trials, the other is an unapproved powder of frequently uncertain contents.

How is trevogrumab dosed, and what about side effects?

In trials, trevogrumab has been given as a subcutaneous or intravenous injection on an infrequent schedule typical of antibodies, but those are trial-protocol doses, not a recommendation, and there is no consumer dosing because the drug is not available. Because it is investigational, its full safety profile is still being characterized, and the honest headline on long-term safety is "not yet established."

On dosing, the only meaningful figures come from the clinical program: the sarcopenia study was a three-month course of subcutaneous REGN1033 at trial-defined doses, and COURAGE tests defined trevogrumab doses (in the range of a few hundred milligrams) layered onto semaglutide (ClinicalTrials.gov NCT01963598; NCT06299098, retrieved 2026-06-16). These describe what was studied, not anything to replicate. There is no reconstitution-and-inject protocol to share, and we deliberately do not provide one, because trevogrumab is a clinical biologic rather than a research-peptide powder.

On safety, antibodies as a class can cause injection-site or infusion reactions and, rarely, immune responses, and any drug that changes body composition warrants careful long-term study. Trevogrumab's specific risk profile is still being defined inside ongoing trials, so the responsible statement is that it has been tolerated well enough to keep advancing through Phase 2, but its long-term human safety is not yet established. That is exactly the kind of uncertainty a regulated approval process is designed to resolve.

Can you buy trevogrumab, and is it legal?

No. Trevogrumab is an investigational drug that is not approved by any regulator and is not sold anywhere; unlike research peptides, it is not part of the gray market, and there is no legitimate way to obtain it outside of a clinical trial. Its legal status is simply that of an unapproved biologic in development.

This is the cleanest difference between trevogrumab and most compounds covered on this site. Research peptides like follistatin-344 or BPC-157 circulate as "research use only" powders that people buy and use off-label, with all the authenticity and safety risks that implies. Trevogrumab does not exist in that channel: it is a manufactured biologic that Regeneron administers within registered trials. If you see "trevogrumab" advertised for sale, treat it as a serious red flag for a mislabeled or counterfeit product, because the genuine drug is not commercially available. For how unapproved compounds are classified more broadly, see are peptides legal.

The practical implication is short: there is no protocol, no vendor, and no dose to act on here. The only legitimate way a person encounters trevogrumab today is as a participant in a clinical trial, under medical supervision.

A realistic look at expectations

Trevogrumab is a genuinely interesting clinical-stage antibody, but it is investigational, its muscle-function benefits have been hard to prove, and its most promising use (preserving muscle during GLP-1 weight loss) rests on one ongoing Phase 2 trial. Calibrated expectations mean treating it as a promising research story, not a product or a proven therapy.

Two honest caveats sit on top of the excitement. First, the myostatin-antibody field has a track record of raising lean mass on scans without clearly improving real-world strength, which is why several earlier drugs in the class were discontinued. Second, the COURAGE muscle-preservation result, while encouraging, is interim Phase 2 body-composition data; whether it translates into better long-term outcomes, and whether the drug is approved at all, remains open. The disciplined view is that trevogrumab is one to watch, not one to chase.

Frequently Asked Questions

The bottom line

Trevogrumab is a clear example of why the "peptide" label gets overused. It is a fully human monoclonal antibody from Regeneron that neutralizes myostatin to release the brake on muscle, and it has nothing in common with the research-peptide powders it is so often grouped with except a shared target. Its mechanism is well defined, and its current obesity work, preserving muscle while GLP-1 drugs burn fat, is one of the more interesting ideas in the muscle-loss field.

The discipline is to match that interest with honesty: trevogrumab is investigational, its sarcopenia chapter showed how hard functional benefit is to prove, its best evidence so far is one ongoing Phase 2 trial, and it is not approved, not for sale, and not something anyone can responsibly obtain outside a study. If you take one thing from this hub, let it be the distinction between a precision clinical biologic and a gray-market peptide. From here, the natural next reads are the follistatin-344 guide, how peptides work, and are peptides legal.

Sources

• Wikipedia. "Trevogrumab." Retrieved 2026-06-16. https://en.wikipedia.org/wiki/Trevogrumab
• ClinicalTrials.gov. "A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Safety and Efficacy of 3-month Subcutaneous REGN1033 Treatment in Patients With Sarcopenia" (NCT01963598). Retrieved 2026-06-16. https://clinicaltrials.gov/study/NCT01963598
• ClinicalTrials.gov. "A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity (COURAGE)" (NCT06299098). Retrieved 2026-06-16. https://clinicaltrials.gov/study/NCT06299098
• Regeneron Pharmaceuticals. "Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 Receptor Agonist-induced Weight Loss by Preserving Lean Mass Presented at EASD." 2025-09-17. Retrieved 2026-06-16. https://www.globenewswire.com/news-release/2025/09/17/3151728/0/en/Results-from-Phase-2-COURAGE-Trial-Demonstrating-Potential-to-Improve-Quality-of-GLP-1-receptor-agonist-induced-Weight-Loss-by-Preserving-Lean-Mass-Presented-at-EASD.html
• Mastaitis, J., et al. "GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates." Nature Communications, 2025. Retrieved 2026-06-16. https://www.nature.com/articles/s41467-025-59485-9
• DrugBank. "Trevogrumab" (DB15159). Retrieved 2026-06-16. https://go.drugbank.com/drugs/DB15159
• KEGG. "Trevogrumab" (D11242). Retrieved 2026-06-16. https://www.kegg.jp/entry/D11242
• Wikipedia. "Bimagrumab." Retrieved 2026-06-16. https://en.wikipedia.org/wiki/Bimagrumab